ArticleJournal of blood medicine2026
Correlation Between Von Willebrand Factor, Thrombin-Antithrombin Complex, and Disease Severity in Sickle Cell Disease: Implications for Thrombosis.
Article in Journal of blood medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sickle cell disease (SCD) is a hypercoagulable state characterized by elevated procoagulant factors, including Von Willebrand factor (VWF), and enhanced thrombin generation, marked by increased thrombin-antithrombin complex (TAT). Research on VWF and TAT activity during vaso-occlusive crises (VOC) remains scarce in our region. Objective: To determine VWF antigen and TAT complex serum levels in SCD during steady state and VOC, and correlate these with disease severity. Methodology: This cross-sectional study evaluated 30 SCD patients during VOC and re-evaluated the same cohort during their steady state. A control group of 30 HbAA individuals was included. Serum was analyzed for VWF and TAT complex. Analysis of Variance (ANOVA) and Pearson correlation tests were utilized (p < 0.05). Results: Mean VWF levels were highest during VOC (500.9 ± 175.6 ng/mL), followed by steady state (421.5 ± 130.9 ng/mL) and controls (395.0 ± 115.2 ng/mL) (p=0.014). TAT complex levels were highest during VOC (28.9 ± 10.4 ng/mL) compared to steady state (24.1 ± 7.8 ng/mL) and controls (4.0 ± 4.2 ng/mL) (p<0.001). Steady-state VWF positively correlated with TAT (r = 0.458, p = 0.011), while steady-state TAT positively correlated with disease severity (r = 0.401, p = 0.028). Conclusion: VWF and TAT levels are significantly elevated in SCD patients, with further accentuation during VOC. These elevations strongly correlate with disease severity and specific clinical complications, establishing them as vital markers for evaluating thrombotic risk in SCD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.